‘Total Disconnect’ Between French Drug Spending Plans And Reality

This year’s French social security financing bill contains plenty for the pharmaceutical industry to complain about, including price cuts and rebates, although a controversial plan aimed at reducing the prices of older drugs has been put on the back burner.